Introduction {#S0001}
============

Managing pain following orthopedic surgery can be challenging as post-orthopedic surgery patients report high pain scores, likely related to the nature of bone injuries.[@CIT0001],[@CIT0002] Effective pain management is important because uncontrolled postoperative pain is associated with several adverse outcomes, including delayed recovery, longer hospital stays, and increased morbidity.[@CIT0003],[@CIT0004] Guidelines for the management of postoperative pain strongly recommend an integrative approach, including the use of multimodal analgesia.[@CIT0005],[@CIT0006] This approach advocates the use of a variety of medications, routes of administration, and techniques that result in a synergistic and more effective approach to pain relief.[@CIT0005],[@CIT0007] Multimodal analgesia regimens are also a central component for enhanced recovery after surgery protocols and procedure-specific pain management initiatives.[@CIT0008],[@CIT0009] A major goal of multimodal pain management is the reduction in the need for opioids, which are associated with several well-documented risks (eg, dependence, abuse, diversion, hyperalgesia) and adverse events (AEs), including respiratory depression, nausea, vomiting, and constipation.[@CIT0010]--[@CIT0012]

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly recommended for incorporation in multimodal postoperative pain management regimens following orthopedic surgery.[@CIT0013]--[@CIT0015] These agents have analgesic, anti-inflammatory, and opioid-reducing effects; however, they can be associated with AEs (eg, bleeding, cardiovascular complications, and renal effects) that have the potential to limit their use.[@CIT0013],[@CIT0016] Thus, a detailed examination of the safety profile of investigational NSAIDs or new formulations of known NSAIDs is important.

Meloxicam is a long-acting NSAID with preferential cyclooxygenase (COX)-2 inhibition that has anti-inflammatory, analgesic, and antipyretic properties.[@CIT0017] The drug has been available in an oral formulation for many years; however, a limitation of oral meloxicam is poor aqueous solubility that results in slow absorption and a slow onset of action. This is evidenced by an observed peak plasma concentration that occurs 9 to 11 hrs after an orally administered dose of 30 mg.[@CIT0017] Consequently, oral meloxicam is not suitable for the treatment of acute pain. A novel nanocrystal formulation of meloxicam that can be given by intravenous (IV) bolus injection is being developed for moderate to severe pain management alone or in combination with other analgesics.

The safety and efficacy of meloxicam IV was investigated in three Phase 2 clinical trials using validated models for both hard- and soft-tissue surgeries, including bunionectomy, hysterectomy, and dental impaction.[@CIT0018]--[@CIT0020] In these studies, once-daily administration of meloxicam IV provided onset of analgesia as early as 15 mins post-dose, with maintenance of analgesic effect over a 24-hr period in subjects with moderate-to-severe postoperative pain. The drug was generally well tolerated, with an incidence of AEs that was comparable to placebo.

In phase 3 trials using validated models of subjects with postoperative pain following soft-tissue surgery (abdominoplasty)[@CIT0021] and hard-tissue surgery (bunionectomy),[@CIT0022] subjects who received meloxicam IV had a statistically significant reduction in pain intensity versus subjects randomized to placebo. In both studies, meloxicam IV demonstrated a safety profile comparable to placebo with respect to number, severity, and frequency of AEs.

A recent phase 3 multi-center, randomized, double-blind, placebo-controlled study evaluated the safety and tolerability of meloxicam IV 30 mg in adults scheduled to undergo major elective surgery with an inpatient hospital stay \>24 hrs (clinicaltrials.gov identifier: NCT02720692).[@CIT0023] The primary objective, evaluation of meloxicam IV safety and tolerability, was assessed by incidence of AEs and serious AEs, physical examination, vital signs, clinical tests, electrocardiograms (ECGs), wound evaluation, and postoperative opioid consumption. The clinical study enrolled a heterogeneous subject population in order to study the use of meloxicam IV under a wide range of procedures, including both hard- and soft-tissue surgeries. Here, the safety and tolerability findings from a subpopulation of subjects in this study who underwent orthopedic surgeries are reported.

Methods {#S0002}
=======

Study Design {#S0002-S2001}
------------

This was a post hoc subgroup analysis of a phase 3 multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety of meloxicam IV in adult subjects undergoing major surgery, including, but not limited to, orthopedic procedures (eg, total hip or knee replacement), open or laparoscopic abdominal surgeries, or gynecological surgeries and a range of other soft-tissue surgeries (clinicaltrials.gov identifier: NCT02720692).[@CIT0023] The study was conducted at sites in the United States, Canada, Australia, and New Zealand ([[Supplemental Table 1](https://www.dovepress.com/get_supplementary_file.php?f=216219.docx)]{.ul}) between March 2016 and April 2017; all subjects provided written informed consent. The protocol was reviewed and approved by the central Institutional Review Board (IRB) with additional review by local IRBs where required and was performed according to the International Conference on Harmonisation Good Clinical Practice Guideline for Industry and, where applicable, the principles of the Declaration of Helsinki. Study randomization was stratified into two groups: subjects who underwent an orthopedic procedure and those who underwent a non-orthopedic procedure. This post hoc analysis evaluated the safety and opioid-reducing effects of meloxicam IV among the subgroup of subjects in the strata undergoing a range of orthopedic procedures ([Table 1](#T0001){ref-type="table"}).Table 1Summary of Orthopedic Surgery TypesOrthopedic Surgery, n (%)Meloxicam IV\
30 mg (n=283)Placebo (n=96)Overall (N=379\*)Total knee replacement117 (41.3)39 (40.6)156 (21.6)Complex foot52 (18.4)19 (19.8)71 (9.8)Total hip replacement50 (17.7)18 (18.8)68 (9.4)Bunionectomy40 (14.1)13 (13.5)53 (7.4)Spinal surgery10 (3.5)3 (3.1)13 (1.8)Total shoulder replacement7 (2.5)1 (1.0)8 (1.1)Complex shoulder surgery6 (2.1)2 (2.1)8 (1.1)Total ankle replacement1 (0.4)01 (0.1)Orthopedic trauma01 (1.0)1 (0.1)[^1][^2]

Dosing {#S0002-S2002}
------

Subjects who met postoperative randomization eligibility criteria were randomized (3:1 using a computer-generated block randomization scheme) to IV treatment with meloxicam 30 mg or placebo, administered as a bolus injection every 24 hrs. Randomization was stratified by subjects greater than 65 years with mild renal impairment (glomerular filtration rate 60‒89 mL/min/1.73 m^2^) versus other. Subjects received the first dose of study medication within 6 hrs of the end of surgery, with additional doses administered as clinically appropriate up to a maximum of seven doses.

Concomitant NSAIDs were prohibited within 7 days prior to surgery. During surgery, subjects received the standard of care anesthesia and analgesic regimens (excluding the use of NSAID medication) according to the clinical practice of the surgeon based on the surgery type. Subjects with inadequately controlled pain could receive standard of care rescue medication. Although opioid analgesics were the most common type of rescue medication, any rescue analgesic (except for other NSAIDs) was acceptable according to the standard practice of the study site.

Key Eligibility Criteria {#S0002-S2003}
------------------------

Male and non-pregnant, non-lactating females 18‒80 years of age (inclusive) with a body mass index (BMI) ≤40 kg/m^2^, scheduled to undergo major elective surgery, and in the opinion of the surgeon performing the procedure would require post-surgical IV analgesia, to remain in an inpatient setting for 24--48 hrs, and to receive at least two study doses were eligible for enrollment. Subjects were also required to meet postoperative randomization criteria that included: (1) the ability to achieve hemostasis and surgical incision closure prior to operating room discharge; (2) the surgical procedure was not longer than 12 hrs and did not require use of \>2 units of packed red blood cells or platelets; (3) the subject was expected to have sufficient pain to require IV analgesia; and (4) there was no evidence of respiratory insufficiency, clinically significant hypotension, bradycardia, coagulopathy, or any other abnormality, during or following surgery that, in the investigator's opinion, could significantly increase the risks of study participation.

Subjects were excluded if they had an allergy to meloxicam or other NSAIDs or excipients, were undergoing a surgical procedure in which NSAIDs were contraindicated, or had planned/actual admission to the intensive care unit. Elevated aminotransferases; history of HIV, hepatitis B, hepatitis C; significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric conditions; myocardial infarction or coronary artery bypass graft surgery within 12 months; active or recent bleeding (within 6 months), gastrointestinal ulceration, or known bleeding disorder; and history of alcohol abuse and positive results during drug screen were also exclusion criteria.

Assessments {#S0002-S2004}
-----------

Safety evaluations included assessment of AEs, clinical laboratory tests, vital signs, ECG findings, wound assessments, and opioid consumption. All AEs were classified according to the Medical Dictionary for Regulatory Activities (Version 18.1). AEs and serious AEs were assessed by investigator for intensity and causality. Particular attention was paid to AEs of special interest related to concerns associated with NSAIDs (bleeding, cardiovascular, hepatic, injection site, renal, thrombotic, and wound healing events). Surgical wound healing was evaluated by the investigator prior to discharge and at follow-up visit to determine whether healing was following a normal course and was evaluated on an 11-point scale (0‒10). Opioid consumption was assessed as the IV morphine equivalent dose (IVMED) in milligrams at various time intervals: Day 1 (0‒24 hrs), Day 2 (24‒48 hrs), Day 3 (48‒72 hrs), Days 1‒2 (0‒48 hrs), and Days 1‒3 (0‒72 hrs). Time to first opioid for pain management was also assessed in an ad-hoc analysis.

Statistical Analysis {#S0002-S2005}
--------------------

This paper presents descriptive results from a post hoc subgroup analysis of a phase 3 safety study. The safety study sample size was chosen not based on any statistical assumption, but to meet regulatory requirement for total exposure. Sample size for subjects in the orthopedic strata was not pre-specified. The safety analysis population included all subjects treated with study drug. Safety endpoints were summarized descriptively. Differences between groups for opioid consumption were analyzed using an ANCOVA model that included treatment and analysis site. A non-parametric approach using rank-based analysis (as assessed by Cochran-Mantel-Haenszel row mean difference test) controlling for analysis site was also performed as a sensitivity analysis. For time to first opioid use, time to event analyses included Kaplan-Meier Log-rank test for survival curves and the Cox proportional hazards model for the determination of hazard ratio (controlling for site).

Results {#S0003}
=======

Subjects {#S0003-S2001}
--------

A total of 379 subjects underwent orthopedic surgery; demographic and surgical characteristics are summarized in [Table 2](#T0002){ref-type="table"}. The overall characteristics of subjects undergoing orthopedic surgery were generally similar between meloxicam IV- and placebo-treated subjects. The most common orthopedic surgeries were total knee replacement, complex foot surgery, total hip replacement, and bunionectomy ([Table 1](#T0001){ref-type="table"}). A summary of the extent of study drug exposure is summarized in [Table 3](#T0003){ref-type="table"}. The majority of subjects undergoing orthopedic surgery (\>85%) received either two or three doses of study medication.Table 2Summary of Subject DemographicsCharacteristicsMeloxicam IV\
30 mg (n=283)Placebo (n=96)Age (years) -- mean ± SD59.7 ± 10.9059.5 ± 12.06Age ≥65 years, n (%)109 (38.5)37 (38.5)Sex, n (%) Male105 (37.1)30 (31.3) Female178 (62.9)66 (68.8)Race, n (%) White249 (88.0)86 (89.6) Black or African American30 (10.6)6 (6.3) Asian3 (1.1)3 (3.1) Multiple1 (0.4)1 (1.0)Ethnicity, n (%) Hispanic or Latino30 (10.6)12 (12.5) Neither Hispanic nor Latino253 (89.4)84 (87.5)Baseline BMI (kg/m^2^) -- mean ± SD30.2 ± 4.729.8 ± 4.8Surgery duration (hr) -- mean ± SD1.3 ± 0.771.4 ± 0.95High risk, n (%)79 (27.9)26 (27.1)Time (hr) from end of surgery to first dose -- mean ± SD2.1 ± 1.472.2 ± 1.46[^3] Table 3Summary of Study Doses Administered by Surgery TypeNumber of Doses ReceivedOrthopedic Surgery (N=379)Meloxicam IV (n=283)Placebo (n=96)1 Dose7 (2.5)3 (3.1)2 Doses150 (53.0)52 (54.2)3 Doses97 (34.3)34 (35.4)4 Doses23 (8.1)6 (6.3)5 Doses2 (0.7)1 (1.0)6 Doses1 (0.4)07 Doses3 (1.1)0[^4]

Adverse Events {#S0003-S2002}
--------------

The overall incidence of AEs was similar between meloxicam IV-treated and placebo-treated subjects ([Table 4](#T0004){ref-type="table"}). AEs were mild or moderate in both treatment groups. Serious AEs occurred in 2.5% of meloxicam IV-treated subjects and 4.2% of placebo-treated subjects. All serious AEs were reported as single-incident events in individual subjects with the exception of post-procedural pulmonary embolism in two (0.7%) meloxicam IV-treated subjects. Both events of post-procedural pulmonary embolism were assessed by the investigator as unrelated to study treatment. Discontinuations due to an AE occurred in a single subject from the meloxicam IV group. There were no deaths reported during or following treatment in the study.Table 4Summary of Adverse Events in Subjects Undergoing Orthopedic SurgeryEventMeloxicam IV (n=283)Placebo (n=96)EventsNo. Subjects (%)EventsNo. Subjects (%)≥1 Event410183 (64.7)16066 (68.8)Intensity Mild248137 (48.4)8644 (45.8) Moderate14793 (32.9)7243 (44.8) Severe1512 (4.2)22 (2.1)Relationship Not related301155 (54.8)10049 (51.0) Possibly related10162 (21.9)5732 (33.3) Probably related84 (1.4)22 (2.1) Definitely related0011 (1.0)AE-related treatment discontinuation11 (0.4)00Most Common Events (≥3%) Nausea7067 (23.7)3430 (31.3) Constipation3535 (12.4)1313 (13.5) Vomiting2320 (7.1)1010 (10.4) GGT increased1717 (6.0)55 (5.2) Headache1615 (5.3)55 (5.2) Anemia1312 (4.2)44 (4.2) Insomnia88 (2.8)55 (5.2) Dizziness66 (2.1)76 (6.3) Hypotension88 (2.8)44 (4.2) Pruritus88 (2.8)44 (4.2)[^5]

The most common AEs were gastrointestinal events (ie, nausea, constipation, vomiting), headache, and increased gamma-glutamyltransferase ([Table 4](#T0004){ref-type="table"}). Although there were no statistical comparisons made, subjects in the meloxicam IV group had numerically lower incidence of common opioid-related AEs compared with the placebo group, including nausea, constipation, vomiting, and pruritus.[@CIT0012],[@CIT0024]

Adverse Events of Special Interest {#S0003-S2003}
----------------------------------

The incidence of AEs of special interest is summarized in [Table 5](#T0005){ref-type="table"}. Across treatment groups, the number and frequency of bleeding, hepatic, renal, cardiovascular, wound healing, and injection site events were generally similar. Renal events in meloxicam IV subjects included acute kidney injury (n=2 \[0.7%\]) and blood urea nitrogen (BUN) increased (n=2 \[0.7%\]). One report of acute kidney injury occurred 14 days after administration of meloxicam IV in a subject with an elevated creatinine value and 2+ urine protein before dosing. The other report occurred 1 day after the first dose of meloxicam IV and resolved the next day in a subject whose creatinine values were within the reference range before and after dosing. Investigators assessed renal events as mild or moderate in intensity. One event of increased BUN was considered possibly related to study treatment; all other renal events were assessed as not related to study medication. Thrombotic events in meloxicam IV subjects included post-procedural pulmonary embolism (n=2 \[0.7%\]) and deep vein thrombosis (n=1 \[0.4%\]). All three subjects underwent knee surgery and had concomitant medical conditions (coronary artery disease, hypertension, dyslipidemia with a previous myocardial infarction) that predisposed them for thromboembolic phenomena.Table 5Adverse Events of Special Interest in Subjects Undergoing Orthopedic SurgeryEventMeloxicam IV (n=283)Placebo (n=96)No. Subjects (%)No. Subjects (%)Bleeding13 (4.6)4 (4.2)Cardiovascular3 (1.1)2 (2.1)Hepatic27 (9.5)7 (7.3)Injection site reactions00Renal4 (1.4)0Thrombotic3 (1.1)0Wound healing12 (4.2)3 (3.1)[^6]

Laboratory Values, Vital Signs, Wound Healing {#S0003-S2004}
---------------------------------------------

Laboratory assessments related to bleeding risk and to renal and hepatic function were of interest because these are known to be class effects of NSAIDs. All laboratory measures that were out of normal range and assessed by the site investigator to be clinically relevant were recorded as AEs. Shift plots were used to evaluate changes in clinical laboratory values. Shifts from normal were similar between meloxicam IV- and placebo-treated subjects for hematocrit (60.8% versus 59.5%), hemoglobin (56.8% versus 50.0%), and platelets (28.5% versus 31.1%). The incidence of clinically significant vital sign parameters that were reported as AEs was low and was generally similar between the meloxicam IV and placebo groups, respectively (hypotension 2.8% versus 4.2%; pyrexia 3.5% versus 3.1%; postoperative fever 1.8% versus 3.1%; hypertension 1.1% versus 1.0%; tachycardia 0.7% versus 0%; hypoxia 0.4% versus 1.0%; orthostatic hypotension 0.4% versus 0%; procedural hypotension 0.4% versus 0%; respiratory rate decreased 0% versus 1.0%; and tachypnea 0.4% versus 0%). None of the ECG shifts from normal to abnormal was considered clinically significant in either treatment group.

The mean assessment score of investigator satisfaction with wound healing 1 day following the last study dose prior to discharge was similar for meloxicam IV-treated subjects and placebo-treated subjects ([Table 6](#T0006){ref-type="table"}). There was a low incidence of clinically significant findings on wound evaluation, with an incidence generally similar between the meloxicam IV and placebo groups ([Table 6](#T0006){ref-type="table"}).Table 6Summary of Wound Assessment ParametersMeloxicam IV (n=283)Placebo (n=96)Investigator Satisfaction with Surgical Wound Healing\* LSD + 1/Discharge9.6 ± 0.699.5 ± 0.86 LSD + 7 days9.4 ± 1.019.4 ± 0.89Clinically Significant Wound Assessment Parameters, n (%) Erythema3 (1.1)1 (1.1) Drainage1 (0.4)1 (1.1) Edema1 (0.4)0 Induration1 (0.4)0 Hematoma1 (0.4)0[^7][^8]

Opioid Consumption {#S0003-S2005}
------------------

The most common non-opioid rescue medications were acetaminophen, gabapentin, and pregabalin. Among orthopedic subjects, meloxicam IV was associated with significantly lower mean total opioid consumption compared with the placebo group (36.8 mg versus 50.3 mg IVMED; *P*=0.0081). Total opioid consumption was significantly reduced among meloxicam IV-treated subjects compared with the placebo group during most time points, including during Day 1 (0‒24 hrs), Day 2 (24‒48 hrs), Days 1‒2 (0‒48 hrs), and Days 1‒3 (0‒72 hrs) ([Table 7](#T0007){ref-type="table"}, [Figure 1](#F0001){ref-type="fig"}). There was a nonsignificant decline in total opioid consumption in the meloxicam IV group during Day 3 (48‒72 hrs). In an ad-hoc analysis, time to first opioid rescue medication was significantly longer in the meloxicam IV group compared with the placebo group (hazard ratio 0.615; 95% CI 0.479, 0.789; *P*=0.0001).Table 7Summary of Total Opioid Consumption (Mean ± SD\*) by Time IntervalIntervalMeloxicam IVPlacebo0‒24 hrs n28296 Mean ± SD22.1 ± 22.7531.1 ± 30.87 *P* value0.003224‒48 hrs n27593 Mean ± SD11.7 ± 18.6715.7 ± 23.92 *P* value0.036248‒72 hrs n12641 Mean ± SD5.3 ± 11.138.6 ± 22.80 *P* value0.21780‒48 hrs n28296 Mean ± SD33.5 ± 37.0546.3 ± 46.51 *P* value0.00320‒72 hrs n28296 Mean ± SD35.9 ± 40.8650.0 ± 55.59 *P* value0.0037During treatment n28296 Mean ± SD36.8 ± 42.6950.3 ± 55.74 *P* value0.0081[^9][^10] Figure 1Total opioid consumption^a^ by time interval. ^a^Intravenous morphine equivalent dose (mg).**Abbreviations:** IV, intravenous; SE, standard error.

Discussion {#S0004}
==========

Postoperative pain is an acute form of pain that is a consequence of surgical trauma and the subsequent inflammatory reaction.[@CIT0025] Postoperative pain is common, often undermanaged, and associated with a poorer recovery.[@CIT0025],[@CIT0026] Although opioids are a mainstay in the treatment of postoperative pain, the AEs and risks (dependency, overdose, diversion) associated with their use have prompted the investigation of alternative and complementary analgesics.[@CIT0027]--[@CIT0029] NSAIDs have well-documented efficacy in the treatment of postoperative pain and have been shown to have an opioid-reducing effect and, in some cases, the ability to decrease opioid-related AEs (eg, nausea, vomiting, sedation).[@CIT0028],[@CIT0030] However, they can be associated with significant AEs such as bleeding, cardiovascular complications, and renal effects.[@CIT0013],[@CIT0016]

Many orthopedic surgeries (eg, foot and ankle procedures, and total joint replacements) can be performed on an outpatient basis and only require oral analgesics after surgery for pain management.[@CIT0031] However, some complex orthopedic surgeries may require ≥24 hrs of inpatient care and post-surgical IV analgesia.[@CIT0032],[@CIT0033] This study represents a large cohort of subjects undergoing a heterogeneous range of orthopedic procedures that required inpatient care for ≥24‒48 hrs, providing opportunity to evaluate meloxicam IV safety and tolerability in this population.

Results from the current subgroup analysis demonstrate that meloxicam IV 30 mg had a similar AE profile to placebo and had an opioid-reducing effect when administered to subjects with moderate-to-severe pain following orthopedic surgery. The overall rate of AEs was similar between meloxicam IV- and placebo-treated subjects and there were no new safety signals identified.[@CIT0018],[@CIT0020] Most of the AEs were mild or moderate in intensity and considered unrelated to study treatment by the investigator. There was no evidence of an increase in AEs of special interest, such as bleeding, hepatic, renal, cardiovascular, wound healing, and injection site events, which can sometimes be of concern with NSAIDs.[@CIT0013],[@CIT0016] There were also no evident differences between treatment groups for laboratory values, vital signs, ECG, and wound healing. In particular, there were no clinically meaningful differences between meloxicam IV- and placebo-treated subjects for shifts from normal for hematocrit, hemoglobin, or platelets.

Although statistical comparisons were not performed, there was a trend toward a decrease in common opioid-related AEs such as nausea, vomiting, constipation, and pruritus. This is consistent with other studies suggesting that NSAIDs that have an opioid-reducing effect are associated with a decrease in opioid-related AEs.[@CIT0028],[@CIT0034] For example, a meta-analysis of 22-double-blind trials including 2307 patients that evaluated NSAIDs in the treatment of postoperative pain found a positive correlation between the reduction of morphine usage and the incidence of nausea and vomiting.[@CIT0030] This analysis found that for each milligram of morphine spared by NSAIDs, the incidences of postoperative nausea and vomiting were decreased by 0.9% and 0.3%, respectively.[@CIT0030] The benefit was particularly evident in the subgroup of studies conducted in orthopedic surgery, with NSAIDs associated with a 34% reduction in postoperative nausea and vomiting.[@CIT0030] In the current study, meloxicam IV was associated with a significant reduction in total opioid use of \>25%, which corresponded to a total decrease of 12 IVMED. Thus, the reduction in opioid use in the meloxicam IV group in this study may have contributed to a lower incidence of AEs commonly associated with opioid use. Overall, these results suggest that meloxicam IV is a well-tolerated option for use in pain management in patients undergoing orthopedic surgery and its use may contribute to the goal of minimizing the use of opioid medications.

A major limitation of this study is that it is a subgroup analysis of a randomized trial and was not powered to evaluate the statistical significance of differences between treatment groups for the safety variables assessed. An additional limitation is that analgesic needs can be quite different across diverse orthopedic procedures and this study did not assess pain scores as reported by subjects as a measure of analgesic efficacy. Mean opioid consumption was assessed in this study as a surrogate measure of analgesic efficacy.

Conclusion {#S0005}
==========

Overall, meloxicam IV 30 mg administered once daily was generally well tolerated and had an opioid-reducing effect in subjects with moderate to severe pain following orthopedic surgery.
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[^1]: **Note:** \*Safety set (received ≥1 dose of study drug).

[^2]: **Abbreviation:** IV, intravenous.

[^3]: **Abbreviations:** BMI, body mass index; hr, hour; IV, intravenous; SD, standard deviation.

[^4]: **Abbreviation:** IV, intravenous.

[^5]: **Abbreviations:** AE, adverse event; GGT, gamma-glutamyltransferase; IV, intravenous.

[^6]: **Abbreviation:** IV, intravenous.

[^7]: **Note:** \*11-point scale with 0 = "completely unsatisfied" and 10 = "completely satisfied."

[^8]: **Abbreviations:** IV, intravenous; LSD, last study dose.

[^9]: **Note:** \*Intravenous morphine equivalent dose (mg).

[^10]: **Abbreviations:** IV, intravenous; SD, standard deviation.
